Real-world treatment patterns and outcomes in patients with early-stage HCC in the US treated with resection or ablation
Our results highlight the need for post-treatment surveillance and the potential role for neoadjuvant and/or adjuvant treatments to improve outcomes in patients with eHCC treated with resection or ablation.
Authors
- Heide A. Stirnadel-Farrant (ORCID: https://orcid.org/0000-0003-0734-0422)
- Kirema Garcia-Reyes (ORCID: https://orcid.org/0000-0002-9877-1334)
- Neehar D. Parikh (ORCID: https://orcid.org/0000-0002-5874-9933)
- Nehemiah Kebede
- Jenny Hu
- Cindy Wang (ORCID: https://orcid.org/0000-0001-5372-2371)
- Ravi Patel (ORCID: https://orcid.org/0000-0003-2839-6855)
Institutions
- AstraZeneca (United Kingdom) (GB)
- University of Michigan (US)
- Mount Sinai Hospital (US)
- AstraZeneca (Australia) (AU)
- AstraZeneca (France) (FR)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Japan) (JP)
- AstraZeneca (Poland) (PL)
- AstraZeneca (United States) (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Hepatic Oncology
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1080/20450923.2025.2530377
- Citations
- 2
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.64
Funders
- AstraZeneca